HealthMore in Health→
Biopharma Dealmaking Is Staying Active, but the Era of the Megadeal Looks Weaker
Key Takeaways
- Biopharma dealmaking remains strong as large companies prepare for patent expiries.
- The standout change is the relative absence of megadeals.
- Smaller targets are taking priority in the search for future blockbuster products.
DE
DT Editorial Team··via endpoints.news